Table 3.
IC50 values of selected compounds against different breast cancer entities including standard deviation (n=3).
|
|
IC50 [μM] |
||
|---|---|---|---|
|
T‐47D[a,b] |
MCF‐7[a,b] |
BT‐474[a,c,d] |
|
|
6 d |
1.01±0.19 |
11.13±3.85 |
>8.00[e] |
|
10 a |
2.57±0.93 |
3.24±0.82 |
3.93±0.56 |
|
10 b |
1.45±0.09 |
4.33±1.54 |
2.93±0.43 |
|
10 c |
1.58±0.48 |
1.62±0.32 |
2.55±0.40 |
|
entinostat |
2.91±0.89 |
8.98±3.00 |
7.09±1.00 |
|
vorinostat |
3.17±0.39 |
4.55±1.07 |
10.13±3.47 |
[a] invasive ductal carcinoma, not otherwise specified; [b] HR+ (hormone receptor positive); [c] PR+ (progesterone receptor positive); [d] HER2 overexpression; [e] <25 % inhibition at stated concentration